Oct 30 |
Clarity Pharmaceuticals Ltd's (ASX:CU6) top owners are individual investors with 58% stake, while 18% is held by insiders
|
Oct 16 |
Copper-67 SAR-bisPSMA updates
|
Oct 14 |
Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer
|
Sep 19 |
Market Sentiment Around Loss-Making Clarity Pharmaceuticals Ltd (ASX:CU6)
|
Sep 12 |
SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort
|
Aug 23 |
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation
|
Aug 22 |
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
|
Jun 30 |
Codan Leads Three Undervalued Small Caps With Insider Actions In Australia
|
Jun 28 |
Exploring Undervalued Small Caps With Insider Actions In June 2024
|
Jun 27 |
Exploring Undervalued Small Caps With Insider Actions In Australia June 2024
|